

***Criteria for clinical use of immunoglobulin in Australia* (the Criteria)**

# Haematology Conditions - Summary of Criteria Changes

The *Criteria for clinical use of immunoglobulin in Australia* (Criteria) is under a continuous review cycle following release of Version 3 on 22 October 2018. The table below summarises subsequent changes made by medical condition and indication to the Criteria following the publication of Version 3. Changes will be applied immediately to new authorisations and to existing authorisations at the next continuing treatment request, unless otherwise stated. This table will be updated when any change is made.

| **Medical condition** | **Indication/s** | **Summary of changes** | **Date changed** | **Version number** |
| --- | --- | --- | --- | --- |
| Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT) | * Prevention of recurrent bacterial infections due to hypogammaglobulinemia associated with haematological malignancies or post haemopoietic stem cell transplant | * Added links to exclusion criteria. * Updated links for several references. | April 2025 | 3.5 |
| * Change to the conditions for additional dose clarifying that the clinician should list the patient’s current IgG level in the comment box. | December 2024 | 3.4 |
| * The date of test is now only required for the first immunoglobulin level, where more than one Immunoglobulin is tested on the same day. * The interpretation of results values for all Ig levels now include recording of results that are above normal range. * Data entry error has been corrected to remove mandatory field for pre-treatment IgA and IgM levels in qualifying criteria. * The qualifying postscript and review preamble have been updated to allow any specialist to diagnose and review patients with this medical condition. * The trial cessation criterion wording in review criteria has been updated to ensure medical officers know it needs to be completed. * The exclusion criteria has been updated for transplantation related immunomodulatory therapy in the absence of hypogammaglobulinaemia and the link to solid organ transplantation has been removed. | March 2020 | 3.3 |
| * An additional one-off dose is now available during the course of the authorisation in the form of intravenous immunoglobulin or subcutaneous immunoglobulin. * The maintenance dose has been amended to allow 0.4 – 0.6 g/kg every four weeks or more frequently. * Separate doses are now available for intravenous and subcutaneous immunoglobulin administration. | October 2019 | 3.1 |
| Fetal and neonatal alloimmune thrombocytopenia (FNAIT) | * Prevention or treatment of fetal thrombocytopenia or haemorrhage where no previous pregnancy affected by FNAIT * Prevention or treatment of fetal alloimmune thrombocytopenia where unexplained previous fetal death or previous sibling affected by FNAIT * Prevention or treatment of neonatal thrombocytopenia or haemorrhage | * Added information to indication 3 to clarify that this indication only applies to patients up to 3 months of age. * Updated links for several references. | April 2025 | 3.2 |
| * Diagnostic criteria have been updated to replace the term 'Blood Service' with 'Lifeblood'. | November 2023 | 3.1 |
| Haemolytic disease of the fetus (HDF) | * Haemolytic disease of the fetus with high risk of early fetal hydrops or death | * The description and diagnostic criteria has been updated to align with Patient Blood Management Guidelines (PBM) Module 6 – Neonatal and Paediatrics. | March 2020 | 3.1 |
| Immune thrombocytopenic purpura (ITP) - adult | * Newly diagnosed or persistent ITP – subsequent therapy (diagnosis < 12 months) | * Comment section added to qualifying criteria 4 for evidence item 'There is a risk of clinically significant bleeding'. | November 2023 | 3.2 |
| Immune thrombocytopenic purpura (ITP) - children | * Treatment of moderate to severe bleeding in chronic ITP in responsive patients with platelet count less than 30 x 109/L where other therapeutic options have failed or are contraindicated | * The multiplication symbol (x) has been added to the unit of measure in qualifying criteria 3. | November 2023 | 3.2 |
| Neonatal haemochromatosis (NH) | * Pregnant women who have had a previous pregnancy affected by neonatal haemochromatosis | * Added information to indication 2 to clarify that this indication only applies to patients up to 6 months of age. * Updated a citation in the justification for evidence category. * Added links to several references. | April 2025 | 3.2 |
| * The dosing controls have been updated to allow divisions. | March 2020 | 3.1 |
| Post-transfusion purpura (PTP) | * PTP or suspected PTP with thrombocytopenia associated with a risk of life-threatening bleeding | * Diagnostic criteria have been updated to replace the term 'Blood Service' with 'Lifeblood'. | November 2023 | 3.1 |
| Vaccine induced immune thrombotic thrombocytopenia (VITT)/ Vaccine induced prothrombotic immune thrombocytopenia (VIPIT) | * Treatment of vaccine induced immune thrombotic thrombocytopenia (VITT) | * The temporary status of VITT was removed. | November 2023 | 3.0 |
| * The NBA has temporarily added VITT as a new condition in the Criteria to enable supply of intravenous immunoglobulin under the national blood arrangements. This is based on advice received from the NBA’s Haematology Specialist Working Group as well as jurisdictions, including the Commonwealth. | April 2021 | 3.0 |